Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 70

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 70
---
 have a dilutive impact on our existing shareholders. Our articles permit the issuance of an unlimited number of common shares. Future issuance of our common shares will result in dilution to the existing shareholders. Additionally, future sales of our common shares into the public market may lower the market price for our securities, which may result in losses to our shareholders. Sales of substantial amounts of our common shares into the public market, or even the perception by the market that such sales may occur, may lower the market price of our securities.

It is not possible to predict the actual number of shares we will sell under the SEPA, or the gross proceeds resulting from those sales.

Subject to certain limitations in the SEPA and compliance with applicable law, we have the discretion to deliver an advance notice to the Selling Shareholder at any time throughout the term of the SEPA. The number of common shares that are sold through the Selling Shareholder after delivering an advance notice will fluctuate based on a number of factors, including the market price of the common shares during the sales period. Because the price per share of each common share sold will fluctuate during the sales period, it is not currently possible to predict the number of common shares that will be sold or the gross proceeds to be raised in connection with those sales, if any.

We have no history of dividends.

To date, we have not paid any dividends on our outstanding common shares. We currently intend to retain future earnings to finance the operation, development and expansion of our business. We do not anticipate paying cash dividends on our common shares in the foreseeable future. Any decision to pay dividends on our shares will be made at the discretion of our board of directors and will depend on our earnings, financial requirements and other conditions existing at such time. See "Dividend Policy."

Sales of our common shares by the Selling Shareholder or by our other existing shareholders could cause the price of our securities to decline.

Pursuant to the SEPA, the Selling Shareholder may sell up to $15 million of our common shares. In addition, subject to compliance with applicable securities laws, our officers, directors and significant shareholders may sell some or all of their common shares in the future. In addition, subject to compliance with applicable securities laws, our officers, directors and significant shareholders may sell some or all of their common shares in the future. No prediction can be made as to the effect, if any, such future sales of our common shares will have on the market price of our securities prevailing from time to time. However, the future